Health Condition 1: null- community acquired pneumonia and acute exacerbation of chronic bronchitis
Conditions
Interventions
Intervention1: FDC containing Levofloxacin 250 mg + Cefpodoxime 200 tablet: One tablet twice daily for 7 days
Control Intervention1: Levofloxacin 500 mg tablet: One tablet once daily for 7 days
Contro
Sponsors
Dr Sharif Tadvi
Eligibility
Inclusion criteria
Inclusion criteria: Subjects 18 -65 years age of either sex who are able to give voluntary written informed consent and willing to come for follow up. Patients with clinical signs and symptoms of CAP or AECB as per investigators discretion. Chest X-ray findings suggestive of CAP or AECB
Exclusion criteria
Exclusion criteria: Subjects requiring hospitalization Subjects with known or suspected hypersensitivity to penicillins, levofloxacin, cefpodoxime or any the constituents of the formulation. Subjects who have received antimicrobial therapy within 7 days prior to enrollment. Patient who severe complications of RTI. An uncontrolled, unstable clinically significant medical condition; Clinically significant abnormal laboratory, vital sign or ECG findings at screening. Pregnant and lactating females.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Decrease in severity of clinical signs and symptoms from baseline to the end of treatment. Radiological response to treatment. Microbiological response to the treatment. Timepoint: 14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Sharif Tadvi
Outcome results
None listed